You are here: Home » 2021 » March » Archives for 17th

Aptitude Research Examines Benefits of Programmatic Job Advertising

NEW YORK and HERZLIYA, Israel, March 17, 2021 (GLOBE NEWSWIRE) — PandoLogic, the world's leading provider of programmatic recruitment advertising, shared findings from recent report conducted by Madeline Laurano, principal analyst at the talent acquisition industry firm Aptitude Research. Laurano presented the primary research, titled "Don't Get Left Behind: The Programmatic Revolution Starts Now," at this week's Spring HR Tech Conference.

Frustration abounds with traditional job advertising models, given its expensive, inefficient and, most times, ineffective results. These older approaches assume that already stretched recruiters have the time and skills to negotiate, purchase and monitor job advertising investments across a range of job sites, making it no surprise that the ROI is low. In sharp contrast, programmatic job advertising enables companies to re–direct their existing job advertising budgets to modern technology–driven models that provide immediate improvements.

Laurano commented, "In talent acquisition, every company is at a different stage in their advertising and recruitment marketing journey. Although some companies are using programmatic advertising to further their brands, they're not yet applying it as part of their recruiting strategy. Our findings include a maturity model that will help them determine how much of their job advertising budget is being wasted by not using programmatic."

Among the benefits of programmatic job advertising, the research identified the following key points:

  • Companies that leverage programmatic are twice as likely (60 percent versus 29 percent) to reduce time–to–fill
  • These companies are also nearly three times (56 percent versus 19 percent) likely to improve quality–of–hire compared to companies using traditional advertising
  • As opposed to traditional advertising, programmatic job advertising advances diversity hiring efforts (47 percent versus 27 percent)

The research was sponsored by the global programmatic job advertising market leader, PandoLogic.

Jennifer Ravalli, vice president, Marketing at PandoLogic, said, "We were proud to sponsor this much needed research with Aptitude. Programmatic job advertising as a category still has relatively low adoption, despite a strong track record for delivering amazing outcomes for clients. As we look toward job recovery over the next year, we believe programmatic job advertising can be a game changing tool for talent acquisition professionals. This research will help support growth of the category overall, by sharing quantitative data that illuminates the results early adopters are seeing."

Laurano concurred, "We've observed evidence of programmatic in action. For example, it was used by a restaurant company with high turnover. They were able to increase applicant volume by 472 percent, reduce cost–per–applicant by 533 percent plus reduce the monthly recruitment investment by 19 percent."

The Aptitude Research report is available for complimentary download. Please visit https://go.pandologic.com/state–of–programmatic–job–advertising–report to access your copy.

About PandoLogic

PandoLogic's pandoIQ platform enables employers, staffing firms and RPOs to source qualified applicants faster and more efficiently. pandoIQ maximizes job advertising spend through the use of data science, machine learning and proprietary campaign algorithms that fully automate and optimize the job advertising business process. Since 2007, over 125,000 employers and more than 700 digital publishers have benefited from PandoLogic's programmatic solutions resulting in over 5 billion programmatic job campaigns based on more than 200 billion historical job performance data points. To learn more, visit https://pandologic.com/


GLOBENEWSWIRE (Distribution ID 8191314)

Open Society Foundations Call for Immediate Release of OSM Staff Member in Myanmar

London, March 17, 2021 (GLOBE NEWSWIRE) — The Open Society Foundations are deeply concerned by reports that Phyu Pa Pa Thaw, finance manager of OSM (Open Society Myanmar), has been detained in Myanmar. We call for her immediate release. We are alarmed by reports that authorities are seeking to interrogate and arrest other staff members.

The Open Society Foundations have supported the promotion of democracy in Myanmar for decades. This work began in the 1990s when the Foundations funded scholarships and training for students.

Since 2017, OSM has worked with civil society and relevant authorities for the benefit of Myanmar and its people, including to expand inclusive education and access to health care. More information about OSM's work in Myanmar is freely available on this public fact sheet.

Claims of financial misconduct made by the military, including that OSM acted illegally by withdrawing their own funds in local currency from a local bank, are false. Claims that OSM used these funds for illegal purposes are also false. These funds were used for purposes fully within the objectives of OSM. When the military seized power, and media and communications channels, and the banking systems were restricted, OSM moved quickly to secure the funds it would need for operations. The authorities have no legal right to freeze or seize monies in any OSM bank account. OSM is closed and will remain closed.

These allegations suggest a worrying attempt to attack and discredit those who wish for a return to peace and democracy in Myanmar.

We call on the military to immediately release Phyu Pa Pa Thaw and drop these baseless claims against other staff.


GLOBENEWSWIRE (Distribution ID 8191942)

Clever Leaves and Ethypharm Announce German Pharmaceutical Cannabis Partnership

NEW YORK, March 17, 2021 (GLOBE NEWSWIRE) — Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) ("Clever Leaves" or the "Company"), a leading multi–national operator and licensed producer of pharmaceutical–grade cannabinoids, today announced the signing of a supply agreement with Ethypharm ("Ethypharm"), a European manufacturer and distributor of pharmaceutical products, for the sale of medical cannabis extracts produced in Clever Leaves' EU–GMP certified facilities in Colombia. The initial portfolio of products includes high–CBD, high–THC, and balanced CBD and THC formulations developed exclusively by Clever Leaves to meet the regulatory needs of the German market.

The products manufactured under this partnership will be sold within Ethypharm's branded portfolio and will expand Ethypharm's core product offering focusing on Central Nervous System (CNS) diseases and conditions, chronic pain, and critical care treatments. The portfolio will be sold in Germany through Ethypharm's local subsidiary, Ethypharm GmbH, and distributed directly to pharmacies, where they will be dispensed to patients as prescribed medicinal products.

"This partnership with Ethypharm, an established European pharmaceutical company, advances our vision of providing market–leading medical cannabis products to patients. Clever Leaves' focus on high–quality EU–GMP certified production and our international supply chain has positioned us to develop, produce and ship products to end–markets that will have significant impact on patients' treatments", said Kyle Detwiler, CEO of Clever Leaves. "Partnering with an established pharmaceutical company like Ethypharm also allows Clever Leaves to more broadly enter the German pharmaceutical market, which is currently considered one of the most important international medical cannabis markets due to its size, pace of growth, and Germany's clinical credibility in terms of paving the way to entering additional European or international pharmaceutical markets."

“Partnering and working with physicians and pharmacists to improve people's lives is one of Ethypharm's daily ambitions. Today, providing medical cannabis will answer a clear unmet medical need for patients who are not relieved with current treatments. This innovative collaboration on medical cannabis with Clever Leaves is a good example of how Ethypharm has developed new ways to provide patients with the care they need." said Bertrand Deluard, CEO of Ethypharm.

Clever Leaves boasts multiple international certifications including a Good Manufacturing Practices (GMP) Certification by INVIMA; Good Agricultural and Collecting Practices (GACP) Certification; and European Union Good Manufacturing Practices (EU GMP) Certification.

Ethypharm, was recently awarded a role in the French cannabis experiment in a partnership with Aurora.

About Clever Leaves Holdings Inc.
Clever Leaves is a multi–national cannabis company with an emphasis on ecologically sustainable, large–scale cultivation and pharmaceutical–grade processing as the cornerstones of its global cannabis business. With operations and investments in the United States, Canada, Colombia, Germany and Portugal, Clever Leaves has created an effective distribution network and global footprint, with a foundation built upon capital efficiency and rapid growth. Clever Leaves aims to be one of the industry's leading global cannabis companies recognized for its principles, people, and performance while fostering a healthier global community. Clever Leaves has received multiple international certifications that have enabled it to increase its export and sales capacity from its Colombian operations, including European Union Good Manufacturing Practices (EU GMP) Certification, a Good Manufacturing Practices (GMP) Certification by Colombia National Food and Drug Surveillance Institute – Invima, and Good Agricultural and Collecting Practices (GACP) Certification. Clever Leaves was granted a provisional license in Portugal from Infarmed "" the Portuguese health authority "" which allows Clever Leaves to cultivate, import and export dry flower for medicinal and research purposes. In addition, the Portuguese operation was recently granted certification of compliance with GACP and IMC–GAP.

For more information, please visit https://cleverleaves.com/en/home/ and follow us on LinkedIn.

About the Ethypharm Group
Ethypharm is a European pharmaceutical company focused on two therapeutic areas: the Central Nervous System and Critical Care. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs more than 1,500 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible.

For more information visit www.ethypharm.com and follow on LinkedIn.

Forward Looking Statements
This Press Release includes certain statements that are not historical facts but are forward–looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward–looking statements generally are accompanied by words such as "anticipate," "believe," "continue," "estimate," "expect," "forecasts," "future," "intend," "may," "outlook," "plan," "predict," "potential," "projected," "seek," "seem," "should," "will," "would" and similar expressions (or the negative versions of such words or expressions) that predict or indicate future events or trends or that are not statements of historical matters. Such forward–looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward–looking statements. Factors that may cause such differences include, without limitation, expectations with respect to future operating and financial performance and growth, including if or when Clever Leaves will become profitable; Clever Leaves' ability to execute its business plans and strategy and to receive regulatory approvals; potential litigations; global economic conditions; geopolitical events, natural disasters, acts of God and pandemics, including, but not limited to, the economic and operational disruptions and other effects of COVID–19; regulatory requirements and changes thereto; access to additional financing. The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in Clever Leaves' most recent filings with the SEC. All subsequent written and oral forward–looking statements concerning Clever Leaves and attributable to Clever Leaves or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward–looking statements, which speak only as of the date made. Clever Leaves expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward–looking statements contained herein to reflect any change in its expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Clever Leaves Press contacts:
McKenna Miller
KCSA Strategic Communications
+1347–487–6197
mmiller@kcsa.com

Diana Sigenza
Strategic Communications Director
+57310–236–8830
Diana.siguenza@cleverleaves.com

Clever Leaves Investor inquiries:
Sean Mansouri, CFA or Cody Slach
Gateway Investor Relations
+1949–574–3860
CLVR@gatewayir.com

Clever Leaves Commercial inquiries:
Andrew Miller
Vice President Sales – EMEA, North America, and Asia–Pacific
+1416–817–1336
andrew.miller@cleverleaves.com

Ethypharm Media Contacts:
Avril PONELLE
+ 33 (0)1 41 12 17 20
presse@ethypharm.com

Markus GLADBACH / Christine VOGL–KORDICK
+49 157 71 44 60 98 / +49 172 86 50 982
presse@thecommsduo.com


GLOBENEWSWIRE (Distribution ID 8191804)

LeddarTech Announces the Appointment of Dr Olaf Berlien to Its Board of Directors

QUEBEC CITY, March 17, 2021 (GLOBE NEWSWIRE) — LeddarTech , a global leader in Level 1–5 ADAS and AD sensing technology, is pleased to announce the appointment of Dr Olaf Berlien to its Board of Directors, further enhancing the diversity and industry expertise of the Board.

Dr Berlien possesses over 30 years of experience in senior executive positions specializing in engineering, automotive, and lighting. Notably, until recently, Dr Berlien served as CEO of OSRAM since January 2015.

Before joining OSRAM, Dr Berlien served as CEO of M+W Group, a German company for systems engineering and plant construction and before that, as CEO of the technologies division of ThyssenKrupp, overseeing the elevator and automotive segments as well as the engineering activities. From 1996 until 2002, Dr Berlien was a member of the managing board at Carl Zeiss, a German manufacturer of optical systems and optoelectronics.

Dr Berlien started his career at IBM.

"The LeddarTech Board of Directors is very pleased to welcome Dr Olaf Berlien as its newest member," stated Mr. Michel Brl, Chairman of the Board of LeddarTech. "Olaf's extensive leadership experience in the technology industry, combined with his strategic skills in efficient cross–industry networking, business optimization, and handling pertinent market dynamics, will contribute greatly to the strategy oversight role of the LeddarTech Board," Mr. Brl concluded.

"LeddarTech has, over the past few months, made strategic additions to its Board of Directors," stated Charles Boulanger, CEO of LeddarTech. "LeddarTech's global reach has increased dramatically both in personnel and R&D facilities, the latest being in Israel. LeddarTech has evolved to become a true end–to–end environmental sensing company that addresses sensing and perception challenges across the automotive and mobility value chain," Mr. Boulanger continued. "The appointment of Olaf represents our strategy of bringing the best minds in the industry to share their expertise and guidance as we get closer to becoming the most widely deployed sensing platform in the industry for automotive and mobility," Mr. Boulanger concluded.

Dr Berlien holds a doctorate from the Technical University of Berlin.

About LeddarTech

LeddarTech is a leader in environmental sensing platforms for autonomous vehicles and advanced driver assistance systems. Founded in 2007, LeddarTech has evolved to become a comprehensive end–to–end environmental sensing company by enabling customers to solve critical sensing and perception challenges across the entire value chain of the automotive and mobility market segments. With its LeddarVision sensor–fusion and perception platform and its cost–effective, scalable, and versatile LiDAR development solution for automotive–grade solid–state LiDARs based on the LeddarEngine, LeddarTech enables Tier 1–2 automotive system integrators to develop full–stack sensing solutions for autonomy level 1 to 5. These solutions are actively deployed in autonomous shuttles, trucks, buses, delivery vehicles, smart cities/factories, and robotaxi applications. The company is responsible for several innovations in cutting–edge automotive and mobility remote–sensing applications, with over 95 patented technologies (granted or pending) enhancing ADAS and autonomous driving capabilities.

Additional information about LeddarTech is accessible at www.leddartech.com and on LinkedIn, Twitter, Facebook, and YouTube.

Contact:
Daniel Aitken, Vice–President, Global Marketing, Communications, and Product Management, LeddarTech Inc.
Tel.: + 1–418–653–9000 ext. 232
daniel.aitken@leddartech.com

Leddar, LeddarTech, LeddarEngine, LeddarVision, LeddarSP, LeddarCore, VAYADrive, VayaVision, and related logos are trademarks or registered trademarks of LeddarTech Inc. and its subsidiaries. All other brands, product names, and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9cd83aa2–f283–474a–9b59–9f89023084a9


GLOBENEWSWIRE (Distribution ID 8190469)